A word with Flamma….
Chignolo D’Isola, Bergamo, Italy – June 22, 2021 – Flamma was recently spotlighted in Chimica Oggi-Chemistry Today. The article is entitled “A Word With Flamma” and featured a question and answer segment with Kenneth Drew, Ph.D., VP Flamma USA. Drew speaks about Flamma’s long history, building relationships with customers, reliable supply chains, and much more.
You can read the article by going to this page or you can download it here.
About Flamma:
FLAMMA is a family owned & run, fully integrated CDMO based in Bergamo (near Milan in Northern Italy) established in 1950.
FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.
FLAMMA has four manufacturing facilities all with R&D labs- Italy (2), China, and the USA. Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP production plant. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer’s compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.
The Malvern, PA site located outside Philadelphia provides Flamma with the ability to service customers looking to keep materials within the USA for pre-clinical/early stage clinical development as well as small scale commercial manufacturing.
Being a fully integrated company allows Flamma to move your compounds quickly along their journey taking into consideration all aspects necessary for the success of your project.
Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m3 and over 600 employees, see why Flamma should be your next contract manufacturer. FLAMMA – THE THINKING CDMOTM.